MaxCyte Inc (NASDAQ: MXCT) is a cell engineering technology company that develops and commercializes proprietary Flow Electroporation platform instruments and consumables used by biopharmaceutical companies to engineer cells for therapeutic and research applications. Revenue comes from three streams: instrument sales, recurring sales of disposable Processing Assemblies (PAs), and milestone payments plus sales-based royalties under Strategic Platform License (SPL) agreements with cell therapy developers. MaxCyte has maintained gross margins above 80% for six consecutive years through FY2025, driven by premium-priced instruments and zero cost-of-goods on milestone and royalty revenue. As of December 31, 2025, the company held 31 SPL agreements, with 13 programs in clinical development and one at commercial stage, representing a total potential milestone and royalty opportunity exceeding $2 billion. The company IPO'd in August 2021, raising $184.3 million in net proceeds. CEO Maher Masoud and CFO Douglas Swirsky lead the company, which filed its FY2025 10-K on March 25, 2026.

Revenue model

Three revenue streams: (1) instrument sales at premium prices, (2) recurring disposable Processing Assembly (PA) sales tied to instrument use, and (3) SPL agreement economics including upfront fees, clinical and regulatory milestone payments, and sales-based royalties. Milestone and royalty revenue carries no cost of goods sold, supporting margin expansion as SPL programs advance. As of December 31, 2025, MaxCyte has received over $30 million in cumulative milestone revenue. Four new SPL agreements were signed in 2025.

Products and services

ExPERT platform instruments: ExPERT STx, GTx, and VLx (launched for very large-scale cell engineering, supporting transfection of up to 200 billion cells in under 30 minutes, with FDA Master File support established as of September 2023). Disposable Processing Assemblies (PAs) in single-well and multi-well formats supporting a range of processing volumes for both research and cGMP clinical manufacturing. Master File and Technical File access via Letters of Authorization, supporting customer regulatory submissions with FDA, Health Canada, PMDA (Japan), TGA (Australia), MHRA (UK), and Austrian authorities. Quality management system certified under ISO 9001:2015.

Customers and end markets

Primary customers are biopharmaceutical companies developing cell and gene therapies, including immuno-oncology and inherited disorder programs. SPL customers use MaxCyte instruments in clinical manufacturing under FDA-cleared IND applications or foreign equivalents. As of December 31, 2025, one SPL customer program is at commercial stage and 13 are in clinical development. Secondary customers conduct cell-based research and development. The filing notes that for FY2025, one cell therapy company represented a material portion of revenue (specific percentage not disclosed in excerpts).

Value-chain role

Upstream enabling technology provider. MaxCyte supplies the cell engineering instruments, consumables, and regulatory file infrastructure that biopharmaceutical customers use to manufacture cell therapies. It does not develop or own therapeutic products itself. Its FDA Master File and international Technical Files allow customers to reference MaxCyte's platform data in their own IND, BLA, and equivalent regulatory submissions, creating procedural dependency on MaxCyte's platform within customers' manufacturing and regulatory workflows.

Geographic exposure

Primary market is the United States, supported by FDA Master File. International operations are expanding; Master and Technical Files are established in Canada, Japan, Australia, the United Kingdom, and Austria. International growth may require use of distributors and navigation of country-specific regulatory requirements.

Source: SEC 10-K, filed 2026-03-25

Industry: Services-Commercial Physical & Biological Research Peers: Adaptive Biotechnologies Corp Neogenomics Inc Inotiv Inc Bionano Genomics Inc SomaLogic, Inc. Cytek Biosciences Inc Pacific Biosciences of California Inc NS Wind Down Co., Inc. Seer Inc Thermo Fisher Scientific Inc